Visit Diabetes News from dLife.com

ONGLYZA (saxagliptin) With Metformin as Initial Combination Therapy Significantly Lowered A1C and Demonstrated Significant Improvements Across Key Measures of Glucose Control in Treatment Na ve People With Type 2 Diabetes

Posted on September 09, 2008

September 9, 2008 (Press Release) - Results from a 24-week Phase III study presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA (saxagliptin), an investigational selective inhibitor with extended binding to the dipeptidyl peptidase-4 (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), when used in combination with metformin as an initial therapy, produced significant reductions across all key measures of glucose control studied [glycosylated hemoglobin level (A1C), fasting plasma glu...

Original article link


diabetes , diarrhea , hypertension , type 2 diabetes